K-111 is a PPAR-alpha agonist with potential for treating type 2 diabetes mellitus and hyperlipidemia. It improves insulin resistance, reduces body weight, and ameliorates atherogenic dyslipidemia, with preliminary evidence indicating low toxicity and minimal adverse effects. Reagent grade, for research purpose.
Usually ships within 24 hours.